These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 18474660)

  • 1. Anti-tumour necrosis factor agents and lipid profile: a class effect?
    Garcês SP; Parreira Santos MJ; Vinagre FM; Roque RM; da Silva JA
    Ann Rheum Dis; 2008 Jun; 67(6):895-6. PubMed ID: 18474660
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on prescribing tumor necrosis factor inhibitors.
    Hanauer LB
    Arthritis Rheum; 2002 Jun; 47(3):347-8. PubMed ID: 12115169
    [No Abstract]   [Full Text] [Related]  

  • 3. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-tumour necrosis factor therapy in the West Midlands.
    Bartram D; Sheeran T; Price T; Mulherin D
    Rheumatology (Oxford); 2004 Mar; 43(3):400; author reply 400-1. PubMed ID: 14963219
    [No Abstract]   [Full Text] [Related]  

  • 5. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis.
    Coates LC; McGonagle DG; Bennett AN; Emery P; Marzo-Ortega H
    Ann Rheum Dis; 2008 May; 67(5):729-30. PubMed ID: 18408116
    [No Abstract]   [Full Text] [Related]  

  • 6. Increase in plasma levels of adiponectin after administration of anti-tumor necrosis factor agents in patients with rheumatoid arthritis.
    Nagashima T; Okubo-Fornbacher H; Aoki Y; Kamata Y; Kimura H; Kamimura T; Nara H; Iwamoto M; Yoshio T; Okazaki H; Minota S
    J Rheumatol; 2008 May; 35(5):936-8. PubMed ID: 18464318
    [No Abstract]   [Full Text] [Related]  

  • 7. Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome.
    Wagner AD; Andresen J; Jendro MC; Hülsemann JL; Zeidler H
    Arthritis Rheum; 2002 Jul; 46(7):1965-8. PubMed ID: 12124882
    [No Abstract]   [Full Text] [Related]  

  • 8. Effective co-administration of infliximab and etanercept following the failure of sequential anti-TNF agents in a patient with HLA-B27-associated arthropathy.
    Sheehy C; Murphy E; Barry M
    Rheumatology (Oxford); 2006 Oct; 45(10):1314-5. PubMed ID: 16837474
    [No Abstract]   [Full Text] [Related]  

  • 9. Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-alpha blocking agents: two cases.
    Lourari S; Prey S; Livideanu C; Jamard B; Lamant L; Cantagrel A; Paul C
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):967-8. PubMed ID: 19192017
    [No Abstract]   [Full Text] [Related]  

  • 10. Do TNF-blockers reduce or induce uveitis?
    Cobo-Ibáñez T; del Carmen Ordóñez M; Muñoz-Fernández S; Madero-Prado R; Martín-Mola E
    Rheumatology (Oxford); 2008 May; 47(5):731-2. PubMed ID: 18346974
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations.
    Sfikakis PP; Markomichelakis N; Alpsoy E; Assaad-Khalil S; Bodaghi B; Gul A; Ohno S; Pipitone N; Schirmer M; Stanford M; Wechsler B; Zouboulis C; Kaklamanis P; Yazici H
    Rheumatology (Oxford); 2007 May; 46(5):736-41. PubMed ID: 17403712
    [No Abstract]   [Full Text] [Related]  

  • 12. Maintaining and optimising anti-TNF therapy.
    Somerville M
    Musculoskeletal Care; 2007 Dec; 5 Suppl 1():1-17. PubMed ID: 18050263
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of tumor necrosis factor alpha blockade for enthesitis in spondylarthropathy: comment on the article by Marzo-Ortega et al.
    Olivieri I; Padula A; Scarano E
    Arthritis Rheum; 2002 Dec; 46(12):3396-8; author reply 3398. PubMed ID: 12483753
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TNF inhibition in SLE: where do we stand?
    Aringer M; Smolen JS
    Lupus; 2009 Jan; 18(1):5-8. PubMed ID: 19074162
    [No Abstract]   [Full Text] [Related]  

  • 16. Switching tumor necrosis factor alpha inhibitors in HLA-B27-associated severe heel enthesitis.
    Olivieri I; Scarano E; Padula A; D'angelo S; Cantini F
    Arthritis Rheum; 2007 Dec; 57(8):1572-4. PubMed ID: 18050233
    [No Abstract]   [Full Text] [Related]  

  • 17. Introduction to special section: biologic agents in the treatment of rheumatic diseases-the first decade.
    Yelin E; Katz P
    Arthritis Rheum; 2009 May; 61(5):559. PubMed ID: 19405010
    [No Abstract]   [Full Text] [Related]  

  • 18. Do rheumatology cost-effectiveness analyses make sense?
    Wolfe F; Michaud K; Pincus T
    Rheumatology (Oxford); 2004 Jan; 43(1):4-6. PubMed ID: 14523227
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety of combination therapy with rituximab and etanercept for patients with rheumatoid arthritis.
    Blank N; Max R; Schiller M; Briem S; Lorenz HM
    Rheumatology (Oxford); 2009 Apr; 48(4):440-1. PubMed ID: 19153143
    [No Abstract]   [Full Text] [Related]  

  • 20. Rheumatoid vasculitis treated with infliximab.
    van der Bijl AE; Allaart CF; Van Vugt J; Van Duinen S; Breedveld FC
    J Rheumatol; 2005 Aug; 32(8):1607-9. PubMed ID: 16078342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.